You just read:

ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study

News provided by

ContraVir Pharmaceuticals, Inc.

Mar 29, 2016, 06:00 ET